Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitor + Tenofovir + Chidamide + Lenalidomide in EBV-LPD
NCT07133763Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of tenofovir, tucidinostat, lenalidomide in Epstein-Barr virus-associated lymphoproliferative disorders (EBV-LPD), sponsored by The Affiliated Hospital of Xuzhou Medical University. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
tenofovirtucidinostatlenalidomide
03
Conditions
Epstein-Barr virus-associated lymphoproliferative disorders (EBV-LPD)
Beyond the preview
Go deeper on NCT07133763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07133763.